15 Biggest European Pharmaceutical Companies

Published on November 23, 2022 at 9:36 am by Ramish Cheema in Lists, News

In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies.

Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern day semiconductor, other industries have had their origins in Europe. Just as the first jet engine and the automotive were being thought of and developed in the U.S., their counterparts were also being developed in Europe.

The pharmaceutical sector is another such industry that sees the U.S. and Europe compete in technological advancements. The European pharmaceutical industry was worth $283 billion in 2020, and from then until 2028 it will grow at a compounded annual growth rate (CAGR) of 5.4% to sit at $432 billion by the end of the forecast period, as per the research firm Grand View Market Research. This growth will also see the pharma sector recover from the effects of the coronavirus pandemic, which led to fewer diagnoses and prescription medicine uptake. Other factors driving European growth include the adoption of technology and artificial intelligence throughout the drug industry supply chain, as well as the growing role of hospitals in the healthcare ecosystems as they improve their facilities and develop specialized resources for advanced diseases such as cancer.

Another report, this time from Medgadget, analyses the European pharmaceutical drugs market. This market consists primarily of prescription and over-the-counter drugs and excludes other healthcare options such as vaccines and biotechnological research. The research firm estimates that this market was worth $220 billion in 2019 and it will grow at a 4.5% CAGR until 2027. Patents expiring for core drugs will play a major role in this growth, as more companies are able to manufacture and sell generic products. Additionally, the growth in chronic diseases, such as diabetes, will increase the demand for branded and generic drugs.

Today’s piece will look at the top European pharmaceutical firms, out of which the largest companies are AstraZeneca PLC (NASDAQ:AZN), Novo Nordisk A/S (NYSE:NVO), and Roche Holding AG (SWX:ROG.SW).

Pixabay/Public Domain

Our Methodology

We studied the European healthcare industry to identify which firms are operating in the pharma sector. These were then ranked according to their latest market capitalization.

Biggest European Pharmaceutical Companies

15. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Market Capitalization as of November 22, 2022: $9.27 billion

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is an Irish company that develops treatments for several diseases such as sleep disorders, cancers, leukemia, and tumors. It is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s fiscal third quarter saw the firm grow its revenue by 12% annually and post $930 million in operating cash flow. The firm is aiming to generate $5 billion in revenue by 2025, and secure at least 5 product approvals by the end of this decade.

Insider Monkey’s Q3 2022 survey of 920 hedge funds revealed that 43 had invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s largest shareholder is Bernard Horn’s Polaris Capital Management, which owns 1.4 million shares that are worth $195 million.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of Europe’s biggest pharmaceutical companies, alongside others such as Novo Nordisk A/S (NYSE:NVO), AstraZeneca PLC (NASDAQ:AZN), and Roche Holding AG (SWX:ROG.SW).

14. Vifor Pharma AG (SWX:VIFN.SW)

Market Capitalization as of November 22, 2022: $11.6 billion (1CHF = 1.05USD)

Vifor Pharma AG (SWX:VIFN.SW) is a Swiss pharmaceutical company that develops treatments for iron deficiency, heart patients, and rare renal diseases. It is based in Sankt Gallen, Switzerland.

Vifor Pharma AG (SWX:VIFN.SW) reported 1.1 billion CHF in revenue during the fiscal year 2021, which translated into 282 million CHF in operating profit and 263 million CHF in net income. The Vifor Pharma Group’s net sales grew by 2.8% during the year, with the gross profit margin improving to 63.2%.

Vifor Pharma AG (SWX:VIFN.SW)’s latest market capitalization is $11.6 billion.

13. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Market Capitalization as of November 22, 2022: $17.4 billion

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) is a German pharmaceutical company. It develops treatments for autoimmune and inflationary diseases.

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) beat analyst revenue and EPS estimates during its third fiscal quarter as it reported $924 million in revenue, which allowed the company to raise its 2022 revenue guidance to a high end of $3.61 billion.

54 out of the 920 hedge funds polled by Insider Monkey during this year’s third quarter had invested in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)’s largest investor is John Paulson’s Paulson & Co, which owns 6 million shares that are worth $377 million.

12. Royalty Pharma plc (NASDAQ:RPRX)

Market Capitalization as of November 22, 2022: $19.2 billion

Royalty Pharma plc (NASDAQ:RPRX) is a British firm headquartered in New York that buys royalties and funds drug development in the United States.

Despite the bloodbath in the healthcare sector this year, Royalty Pharma plc (NASDAQ:RPRX)’s shares have bucked the market trend and are up by 3.56% over the year. The firm bought a royalty interest in an mRNA cardiovascular disease prevention drug for $250 million in cash and $160 million in additional payments in November 2022.

Royalty Pharma plc (NASDAQ:RPRX)’s market capitalization is $19.2 billion, and 29 out of the 920 hedge funds part of Insider Monkey’s study for this year’s third quarter had invested in it. Andreas Halvorsen’s Viking Global is Royalty Pharma plc (NASDAQ:RPRX)’s largest investor through a $437 million stake that comes via 10 million shares.

11. argenx SE (NASDAQ:ARGX)

Market Capitalization as of November 22, 2022: $20.7 billion

argenx SE (NASDAQ:ARGX) is a Dutch company that is headquartered in Breda, the Netherlands. The firm develops treatments for polyneuropathy, hematological cancer, airway inflammation, and other autoimmune diseases.

argenx SE (NASDAQ:ARGX) generated $147 million in revenue during its third fiscal quarter, which beat Wall Street estimates by $29 million. The firm’s shares have been performing strongly this year, and are up by 5.9% year to date, making most of their gains during the second half. Additionally, argenx SE (NASDAQ:ARGX) is also on track to receive results from three crucial drug trials next year, which could potentially add more fortune to its future.

36 out of the 920 hedge funds polled by Insider Monkey for their Q3 2022 portfolios had invested in argenx SE (NASDAQ:ARGX). argenx SE (NASDAQ:ARGX)’s largest shareholder is Kurt Von Emster’s VenBio Select Advisor, which owns 1.2 million shares worth $446 million.

10. Genmab A/S (NASDAQ:GMAB)

Market Capitalization as of November 22, 2022: $28.7 billion

Genmab A/S (NASDAQ:GMAB) is a Danish company whose treatments target multiple sclerosis, leukemia, myeloma, solid tumors, and atrophy diseases. It is based in Copenhagen, Denmark.

Genmab A/S (NASDAQ:GMAB)’s Darzalex drug, which is currently part of a partnership with the pharma giant J&J, generated $6 billion in sales last year and $1.85 billion in the first quarter of this year. Furthermore, the drug is estimated to rake in up to $8 billion in sales this year, to bring Genmab A/S (NASDAQ:GMAB) a cool $1.1 billion – $1.2 billion in royalties.

By the end of this year’s third quarter, 12 out of the 920 hedge funds part of Insider Monkey’s research had bought Genmab A/S (NASDAQ:GMAB)’s shares. Out of these funds, Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital is Genmab A/S (NASDAQ:GMAB)’s largest investor. It owns 1.4 million shares that are worth $47 million.

9. Lonza Group AG (SWX:LONN.SW)

Market Capitalization as of November 22, 2022: $38 billion (1CHF = 1.05USD)

Lonza Group AG (SWX:LONN.SW) is an equipment firm that provides products and services for biopharmaceutical development. These enable biopharmaceutical and small molecule drug manufacturing. The firm is headquartered in Basel, Switzerland.

Lonza Group AG (SWX:LONN.SW)’s four business segments have performed well this year. The firm’s Biologics segment has grown sales by 26% for this year’s first half, the Small Molecules division has improved margins to 29% despite the current inflationary wave, the Cell & Gene segment has grown sales by 23%, and Capsule and Health Ingredients have grown by 4% annually as of the first half of 2022.

Lonza Group AG (SWX:LONN.SW)’s latest market capitalization is $38 billion.

8. BioNTech SE (NASDAQ:BNTX)

Market Capitalization as of November 22, 2022: $38.5 billion (1CHF = 1.05USD)

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company. It develops treatments for melanoma, prostate cancer, breast cancer, ovarian cancer, and lung cancer, among others. It is based in Mainz, Germany.

BioNTech SE (NASDAQ:BNTX)’s coronavirus vaccine, made in partnership with Pfizer, has continued to evolve with the pandemic. The latest variant is the bivalent vaccine, and according to data shared by the company in November 2022, this version can grow anti-virus antibodies by as much as 11.1x, significantly higher than the original vaccine’s 2.3x.

Insider Monkey took a look at 920 hedge fund portfolios for their third quarter of 2022 investments and discovered that 18 had held a stake in BioNTech SE (NASDAQ:BNTX). BioNTech SE (NASDAQ:BNTX)’s largest shareholder is Philippe Laffont’s Coatue Management, which owns 421,590 shares that are worth $56 million.

7. Bayer Aktiengesellschaft (OTCMKTS:BAYZF)

Market Capitalization as of November 22, 2022: $54.8 billion

Bayer Aktiengesellschaft (OTCMKTS:BAYZF) is a German pharmaceutical giant. It is one of the oldest companies in the world, after being set up in 1863, and is headquartered in Leverkusen, Germany.

Bayer Aktiengesellschaft (OTCMKTS:BAYZF)’s management has strong growth estimates for the firm’s upcoming years. It expects to grow pharmaceutical sales between 3% and 5% until the end of 2023, alongside similar growth estimates for its other two segments – namely Consumer Health and Crop Sciences. The firm delivered 18% annual revenue growth during its second fiscal quarter.

Bayer Aktiengesellschaft (OTCMKTS:BAYZF) has a $54.8 billion market capitalization.

6. GSK plc (NYSE:GSK)

Market Capitalization as of November 22, 2022: $67.8 billion

GSK plc (NYSE:GSK) is a British biotechnology and pharmaceutical firm. It enables the development of treatments for HIV, cancer, the nervous system, and other disorders.

GSK plc (NYSE:GSK) presented investors with a nice surprise during its third fiscal quarter earnings when it raised its 2022 revenue growth guidance to 8% – 10% from an earlier 6% – 8%. For the first three quarters of this year, the firm’s revenue has grown 19% annually on a constant currency basis. What’s more, well, GSK plc (NYSE:GSK) also aims to grow its operating margin to 15% – 17% from an earlier 13% – 15%.

Insider Monkey’s Q3 2022 survey of 920 hedge funds revealed that 37 had held a stake in GSK plc (NYSE:GSK). GSK plc (NYSE:GSK)’s largest investor is Ken Fisher’s Fisher Asset Management, which owns 12 million shares worth $358 million.

AstraZeneca PLC (NASDAQ:AZN), Novo Nordisk A/S (NYSE:NVO), Roche Holding AG (SWX:ROG.SW), and GSK plc (NYSE:GSK) are some of the biggest European pharmaceutical companies.

Click to continue reading and see 5 Biggest European Pharmaceutical Companies.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

15 Biggest European Pharmaceutical Companies

Published on November 23, 2022 at 9:36 am by Ramish Cheema in Lists, News

Biggest European Pharmaceutical Companies

15. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

14. Vifor Pharma AG (SWX:VIFN.SW)

13. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

12. Royalty Pharma plc (NASDAQ:RPRX)

11. argenx SE (NASDAQ:ARGX)

10. Genmab A/S (NASDAQ:GMAB)

9. Lonza Group AG (SWX:LONN.SW)

8. BioNTech SE (NASDAQ:BNTX)

7. Bayer Aktiengesellschaft (OTCMKTS:BAYZF)

6. GSK plc (NYSE:GSK)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

15 Biggest European Pharmaceutical Companies

Published on November 23, 2022 at 9:36 am by Ramish Cheema in Lists, News

Share

Biggest European Pharmaceutical Companies

15. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

14. Vifor Pharma AG (SWX:VIFN.SW)

13. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

12. Royalty Pharma plc (NASDAQ:RPRX)

11. argenx SE (NASDAQ:ARGX)

10. Genmab A/S (NASDAQ:GMAB)

9. Lonza Group AG (SWX:LONN.SW)

8. BioNTech SE (NASDAQ:BNTX)

7. Bayer Aktiengesellschaft (OTCMKTS:BAYZF)

6. GSK plc (NYSE:GSK)

Share

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff